应用治疗公司 (APLT) 今日盘中股价大跌75.55%,引发投资者热议。
导致该公司股价暴跌的主要原因是,美国食品和药药物管理局 (FDA) 昨日拒绝批准该公司治疗罕见遗传病半乳糖血症的新药 govorestat。FDA 表示,govorestat 的临床申请存在不足之处,令这款产品的上市前景蒙阴影。
分析人士指出,govorestat 是该公司一款潜力巨大的创新药物,如今却遭遇重创,代表公司主要的收入增长来源受到了冲击。因此,市场对公司未来前景产生了巨大担忧,从而引发股价剧烈下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.